Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma's integrated SLNB test result.
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy
Castle will share new data evaluating DecisionDx-Melanoma's i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
04:30pm, Tuesday, 03'rd Mar 2026
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it wil
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down – Here’s Why
03:48am, Sunday, 01'st Mar 2026
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $31.88, but opened at $29.87. Castle Biosciences
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
08:57pm, Thursday, 26'th Feb 2026
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
07:01pm, Thursday, 26'th Feb 2026
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.32 per share a year ago.
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
04:05pm, Thursday, 26'th Feb 2026
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and w
FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publicat
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:01am, Thursday, 19'th Feb 2026
Castle Biosciences (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 09'th Feb 2026
Castle Biosciences (CSTL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
07:00am, Thursday, 05'th Feb 2026
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will
Allspring Emerging Growth Fund Q4 2025 Performance Review
02:24pm, Wednesday, 04'th Feb 2026
Allspring Emerging Growth Fund Q4 2025 Performance Review
Wasatch Micro Cap Fund Q4 2025 Performance Review
08:35am, Wednesday, 04'th Feb 2026
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and p
Derek Maetzold Sells 4,017 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
05:22am, Saturday, 24'th Jan 2026
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Derek Maetzold sold 4,017 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an averag
